Adipose-derived mesenchymal stem cells from obese mice prevent body weight gain and hyperglycemia
Yicheng Qi1, Wen Liu1, Xiangsheng Wang2
1Department of Endocrinology and Metabolism, Renji Hospital, School of Medicine, Shanghai Jiaotong University, No. 160 Pujian Road, Pudong New Area, Shanghai, 200127, China.
Abstract:
Changes that occur to the stem cell microenvironment with disease are a major consideration that may affect the behavior and potential therapeutic efficacy of mesenchymal stem cells (MSCs). The purpose of this study is to evaluate the effects of adipose-derived MSCs (ADSCs) from obese mice with hyperglycemia on body weight and glucose homeostasis. After 10 weeks of high-fat diet, mice were injected with phosphate-buffered saline (PBS) and ADSCs derived from normal mice (N-ADSCs) or obese mice (O-ADSCs), respectively. Mice fed with standard rodent chow were injected with PBS and served as normal controls. Obese mice treated with O-ADSCs showed less body weight gain than those receiving PBS or N-ADSCs. The mice that received ADSCs, especially O-ADSCs, also showed improvement in obesity-related hyperglycemia. In particular, the inguinal fat was reduced in obese mice receiving O-ADSCs compared with other groups, probably caused by the increased lipolysis of inguinal fat. Moreover, ADSC infusion restored insulin receptor (INSR) expression in the muscle of obese mice. Differential expression of the CD90 surface marker was slightly increased, while monocyte chemoattractant protein 1 (MCP-1) was reduced in O-ADSCs compared to N-ADSCs. These data provide a theoretical basis that autologous ADSCs from obese individuals may be more effective for treating obesity and related hyperglycemia.
Insights
Obese mice treated with their own adipose-derived stem cells (ADSCs) showed reduced weight gain and improved hyperglycemia. These findings suggest autologous ADSCs may effectively treat obesity and related metabolic disorders.
Area of Science:
- Stem Cell Biology
- Metabolic Disease Research
- Obesity and Diabetes Studies
Background:
- Disease-induced changes in the stem cell microenvironment impact mesenchymal stem cell (MSC) behavior and therapeutic potential.
- Adipose-derived stem cells (ADSCs) are being investigated for therapeutic applications in metabolic disorders.
Purpose of the Study:
- To evaluate the therapeutic effects of ADSCs from obese mice with hyperglycemia on body weight and glucose homeostasis.
- To determine if autologous ADSCs from obese individuals are more effective for treating obesity-related hyperglycemia.
Main Methods:
- Obese mice on a high-fat diet were injected with phosphate-buffered saline (PBS), normal ADSCs (N-ADSCs), or obese ADSCs (O-ADSCs).
- Normal mice on standard chow injected with PBS served as controls.
- Body weight, glucose homeostasis, inguinal fat mass, insulin receptor (INSR) expression, CD90, and monocyte chemoattractant protein 1 (MCP-1) were analyzed.
Main Results:
- Obese mice treated with O-ADSCs exhibited reduced body weight gain compared to PBS or N-ADSC groups.
- ADSC treatment, particularly with O-ADSCs, improved obesity-related hyperglycemia.
- O-ADSC treatment led to reduced inguinal fat, likely due to increased lipolysis, and restored INSR expression in muscle tissue.
Conclusions:
- Autologous ADSCs from obese individuals demonstrate potential efficacy in treating obesity and associated hyperglycemia.
- O-ADSCs showed distinct expression profiles (increased CD90, reduced MCP-1) compared to N-ADSCs, suggesting disease-specific adaptations.
- These findings support the use of autologous ADSCs as a therapeutic strategy for metabolic disorders.
